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ABSTRACT 
  Kentucky is a disparate state, ranking as one of the top states in incidence, prevalence, 
and mortality for both opioid use disorders (OUD) and cancer.  Due to the high volume of both 
diseases in the state, there is a rising concern about the overlap of these two populations.  Cancer 
and its’ treatment are known to cause chronic pain, defined as daily pain lasting 3 months or 
longer.  Generally, chronic pain patients of any type are known to experience higher rates of 
opioid misuse (21-28%) and opioid dependence (8-12%) than the general population (4.1%, 
0.9% respectively).  The risk of OUD must be considered when initiating long-term opioid 
treatment for chronic pain, since a substance use disorder may result in poor pain control, 
dysimmune effects, and tumor proliferative effects.  
  This program will utilize a transdisciplinary team approach to implement Screening, 
Brief Intervention, and Referral to Treatment (SBIRT) at the University of Kentucky Markey 
Cancer Center (UK MCC) in Lexington, KY to assess cancer survivors’ risk for developing 
OUD, monitor opioid use during the first 12-months of survivorship, and refer patients to 
alternative therapies to reduce reliance on opioids and improve pain management. The 
implementation of the program will be evaluated with a process evaluation and an outcome 
evaluation. Process evaluation metrics for the provider include: performance on trainings; 
administration of assessments, opioid monitoring measures, and pain scales; and rate of opioid 
prescriptions. Outcome evaluation metrics for the participant include: ability to manage pain; 
satisfaction with pain treatment plans; rate of completed referrals to specialists; change in OUD 
monitoring measure scores and number completed; and rate of opioid prescriptions.  The 
program will utilize existing resources through UK Healthcare, the MCC Affiliate Network, and 
the MCC Research Network to implement the program to scale and disseminate findings across 
the state and to stakeholders. 
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1 
TARGET POPULATION AND NEED 
 In the early 1990s, pharmaceutical companies claimed that opioids were not addictive 
and assured medical providers and patients that they were safe to be prescribed with minimal 
supervision.  By 2015, the United States saw dramatic increases in prescription opioid abuse, 
black market sales, and deaths, leading to intensive restrictions for opioid prescribing.1 
Prescription opioids include oxycodone, hydrocodone, codeine, morphine, and many others, 
which proved to be far more addictive than pharmaceutical companies originally claimed.2 The 
restricted access to prescription opioids had unintended consequences: people who could no 
longer have their opioid prescriptions filled began to transition to illegal opioids, like heroin, that 
were often laced with highly-potent synthetic opioids, such as fentanyl. By 2017, overdose and 
mortality rates skyrocketed and the U.S. Department of Health and Human Services department 
declared the opioid epidemic as a national public health emergency.  In 2018, an estimated 130 
people died every day from opioid-related drug overdoses.1 
  While mortality rates are shocking, misuse of prescription opioids is substantially more 
common. In 2018, the Substance Abuse and Mental Health Services Administration (SAMSHA) 
found that across the United States, 9.6 million adults aged 18 or older misused prescription 
opioid pain relievers in the past year, representing approximately 5.6% of young adults aged 18-
25 and 3.6% of adults aged 26 or older.  An estimated 1.5 million adults misused prescription 
pain relievers for the first time in 2018, meaning that approximately 4,400 adults misuse opioids 
for the first time every day.3  
  In addition to the opioid epidemic, the United States has also experienced devastating 
rates of cancer. As of 2017, cancer was the second leading cause of death with 599,108 cases, 
following closely behind heart disease, with 647,457 cases.4  On a national level, as of January 
2 
2019, there were approximately 16.9 million cancer survivors living in the United States, 
representing 5.0% of the US population. The number of cancer survivors in the US is expected to 
increase to 21.7 million people by 2029, and to 26.1 million people by 2040.5 The most common 
cancer sites among survivors includes female breast (23%, 3.6 million), prostate (21%, 3.3 
million), colorectal (9%, 1.5 million), gynecologic (8%, 1.3 million) and melanoma (8%, 1.2 
million).6,7   
  Cancer and its’ treatment are known to cause chronic pain, defined as having pain every 
day for more than 3 months.8  Cancer itself can cause pain in the body, typically from a tumor 
pressing on nerves, bones, or organs.  Cancer screening and treatments can also cause pain, such 
as surgical pain from having a biopsy or tumor removed, or phantom pain after a body part has 
been amputated. Chemotherapy can cause peripheral neuropathy, a set of painful symptoms such 
as tingling or burning caused by damage to nerves, and gastrointestinal problems, such as mouth 
and throat sores that make it painful to eat, drink, or talk.  Lastly, radiation treatments also cause 
pain, such as skin burns, scarring, and sores.9  Patients deserve to have their pain treated, and to 
live a life as pain-free as possible.9   
  In light of the opioid epidemic, there has been investigation of opioid misuse in patients 
with chronic pain in general, since the risk of substance use disorder must be considered when 
initiating long-term opioid treatment.10  In 2012, the National Health Interview Survey (NHIS) 
found that a total of 126 million adults (55.7%) reported some type of pain the last six months, 
with nearly 40 million adults (17.6%) experience severe pain, and approximately 25.3 million 
adults (11.2%) experience chronic pain.11 As seen in Table 1, in 2015, a systematic review of 38 
studies found that the rates of opioid misuse in chronic pain patients averaged between 21%-28% 
(range 95% CI: 13%-38%) and rates of substance use disorder to opioids averaged between 8% 
3 
and 12% (range, 95% CI: 3%-17%).12,13  More information on how the Diagnostic Statistical 
Manuals (DSM) have defined misuse versus dependence can be found in Appendix A. 
 
  Kentucky is one of the United States’ leaders in the opioid epidemic,14 and will be the 
catchment area for this proposal. According to 2019 Census data, there are approximately 4.5 
million people living in the state.  The state is 87.6% white alone, 8.4% Black or African 
American alone, and 4% represent American Indian and Alaskan Natives, Asian, Native 
Hawaiian and other islanders, and those with two or more races. 3.8% of the population identify 
as Hispanic or Latino. The median household income from 2014-2018 was $48,392, with the per 
capita income standing at $26,948 – nearly 17% of the state lives in poverty.15 
  In 2017, Kentucky providers wrote an average of 86.8 opioid prescriptions for every 100 
persons as seen in Figure 1,13 
compared to the  
average US rate of 58.7 
prescriptions.16 According to the 
Centers for Disease Control 
(CDC), in 2017 Kentucky reported 
1,160 deaths related to opioids, 
representing a mortality rate of 27.9 deaths per 100,000 persons, compared to the national 
average of 14.6 deaths per 100,000 persons.16  Given the significantly higher rates of opioid 
prescribing and opioid deaths in the state, it would be reasonable to consider that the rate of 
Table 1. Comparison of Opioid Misuse/Dependence in Chronic Pain Patients and US 
General Population 
 Opioid Misuse Opioid Dependence Disorder 
Chronic pain patients 21-28% 8-12% 
General population  4.1% 0.9% 
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opioid misuse is likely higher than the national average. 
  As one of the most disparate states in the US, Kentucky has also experienced 
disproportionate cancer burden.  Kentucky has consistently ranked as one of the highest cancer 
incidence and mortality rates of in the country, and currently holds the #1 spot with an average of 
520.9 cases per 100,000 people annually between 2012-2016 (see Table 2).17,18 Since the 
inception of the Kentucky Surveillance, Epidemiology, and End Results (SEER) Program of the 
National Cancer Institute (NCI) in 1995 to the most recent data in 2017, there were 233,527 
cases of cancer identified in Kentucky that are still living.19 
 
 Kentucky is well-positioned to be pioneers in ensuring that cancer survivors are having 
their pain treated in the best way possible, with minimal risk of opioid misuse or developing an 
opioid use disorder (OUD).  A substance use disorder may result in poor pain control, and there 
is evidence that opioids can cause dysimmune effects, such as increased inflammation, decreased 
strength of the immune system and lower white blood cell counts, and tumor proliferative 
effects, meaning an increase in the number of cells as a result of cell growth and cell 
division.10,20  In 2019, the University of Kentucky Markey Cancer Center (UK MCC) conducted 
a Community Needs Assessment (currently unpublished) among its patients and caregivers to 
identify barriers to treatment. At the time of the submission of this grant, 13% of community 
survey respondents and 9% of patient survey respondents reported that they used opioid 
prescription medications just for the feeling, more than was prescribed, or were prescribed for 
someone else on a monthly basis or more frequently.  
Table 2. 2016 Age-Adjusted Cancer Rates: 
 Incidence, Mortality, and Survivorship in Kentucky and the United States 
 Cancer Incidence  Cancer Mortality  
Kentucky 520.9 cases per 100,000 people 234.9 cases per 100,000 people 
United States 448.0 cases per 100,000 people 189.8 cases per 100,000 people 
5 
  It is important for healthcare providers to take a transdisciplinary team approach to 
identify at-risk individuals and intervene with non-pharmacologic treatment methods to avoid 
opioid misuse and dependence. There is a large evidence base showing that opioid continuing 
education for healthcare professionals improves their ability to correctly prescribe & administer 
opioids to patients, while reducing readmission for pain related issues and reducing stigma 
surrounding those with opioid use disorder, and increasing providers participation in utilizing 
prescription drug monitoring programs.21,22  
  A study published in 2017 found that cancer survivors are 1.22 times more likely to have 
an active opioid prescription 10-years post-treatment.23  To stem the epidemic in prescription 
opioid–related use among cancer survivors, the American Society of Clinical Oncology formed 
an expert panel to conduct a systematic review of medical literature to develop evidence-based 
guidelines on chronic pain management in cancer survivors. The guidelines included 
recommendations such as screening for pain at every encounter, screening for opioid misuse, 
utilizing physical functionality assessments to determine appropriate care, assessing the risks of 
physical adverse effects of opioids used for pain management,24 and incorporating universal 
precautions to minimize abuse, substance use disorder, and adverse events related to opioids.8 As 
of 2020, there has not been a specific initiative to address opioid use in the cancer community at 
Markey Cancer Center, ultimately leading to the development of this proposal. 
   The Substance Abuse and Mental Health Services Administration (SAMSHA) provides 
funding for Screening, Brief Intervention, and Referral to Treatment (SBIRT) training and 
implementation. SBIRT is the program that will be utilized in this proposal, defined by 
SAMSHA as “an evidence-based practice used to identify, reduce, and prevent problematic use, 
abuse, and dependence on alcohol and illicit drugs,” and is being expanded to include 
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prescription drugs.25 Motivational interviewing is a cornerstone of SBIRT, and will be employed 
to encourage patients to lessen their reliance on opioids and utilize alternative therapies to 
improve their pain management.25 More information can be found in the Program Approach. 
  From 2013-2016, SAMHSA funded Medical Professional Training programs at 
numerous locations across the United States, including Northern Kentucky University and for 
University of Kentucky Research.  Since 2003, SAMHSA has awarded 32 SBIRT grants to 
states, territories and tribal organizations to enhance services for persons with, or at risk for, 
substance use disorders.  Despite the overwhelming rates of opioid dependence and overdose 
death rates, Kentucky has not yet been awarded a state cooperative agreement for SBIRT.26  
 Regarding opioid monitoring resources currently available to the population, the 
University of Kentucky Division of Community Medicine in the Department of Family and 
Community Health established the Central Appalachia Inter-Professional Pain Education 
Collaborative (CAIPEC). The goal of CAIPEC is to improve the delivery of chronic pain 
management to the population of Central Appalachia through an evidence-based and inter-
professional approach. CAIPEC was developed to work with practice-based research network 
clinics and had three main aims: provide quality improvement methods for delivery of clinic 
care, deliver statewide continuing education (CE) activities to address opioid use in patients with 
chronic pain, and develop a multimodal mechanism to disseminate project results to clinics and 
participating providers. The target audience of the program are healthcare professionals 
including: Physicians, Advanced Practice Registered Nurses, Physicians Assistants, Massage 
therapists, Physical therapists, and Behavioral Healthcare Professionals.27  CAIPEC is closely 
tied to the UK Physical Therapy and the UK Interventional Pain Associates teams, providing 
referrals to both when appropriate.  
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CAIPEC also provides Chronic Pain Toolkit, a collection of resources and templates for 
clinics to adapt based on their specific needs, designed to empower healthcare professionals to 
make deliberate changes in their opiate prescribing practices.27 The toolkit is organized into 4 
major sections: 1) Transforming Your Clinic Process, includes an implementation workbook for 
the planning and implementation phases, such as worksheets, sample clinic workflows, etc.; 2) 
Education Links, such as suggested guidelines, educational materials, and PowerPoint slide sets;  
3) Resources, a repository of various instruments, such as physical functionality assessments, 
screening tools, etc.; 4) Maintenance of Certification Part IV Resources, an opportunity for 
providers to get credit for certification completion.  
   While the CAIPEC program offers a wealth of information and resources, it has not been 
disseminated beyond the Family and Community Practice department.  The original onset of the 
program randomly selected eight clinics from the consortium to implement the program. This 
program has shown to be effective, 28 and can likely be adapted to other clinic areas such as 
cancer-related pain.   
  Other resources available UK Markey Cancer Center’s Integrative Medicine team, 
offering services such as massage therapy, music therapy, acupuncture, yoga, Jin Shin Jyutsu and 
others. Additionally, Markey hosts an exceptional Psych-Oncology team of ten social workers. 
Their team focuses on: counseling patients and families after a diagnosis, throughout treatment 
and beyond to help them manage the emotional and social challenges of living with and caring 
for someone with a complex disease; teaching patients how to change behaviors (quitting 
smoking, healthy lifestyle) to ensure the best possible outcome; connecting patients with the 
services and resources they need to manage practical aspects of living with cancer, including 
financial and nutrition counseling, transportation and housing assistance; and informing patients 
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about resources available to them at Markey.  They are a natural bridge between the initiatives of 
the CAIPEC group and the aims of this proposal.  
  To address community outreach and dissemination, the SBIRT intervention could 
potentially be expanded to the Markey Cancer Center Research Network (MCCRN) for further 
evidence of validity and then implemented in all of the Markey Cancer Center Affiliate Network 
(MCCAN) sites as a standard clinic protocol. MCCRN is comprised of 7 research sites who are 
all part of the Markey Cancer Center Affiliate Network. MCCAN is comprised of 19 hospitals 
across the state of Kentucky and encompasses the entire catchment area of MCC. 
PROGRAM APPROACH 
 The main goal for Screening, Brief Intervention, Referral to Treatment (SBIRT), is to 
improve community health by reducing the prevalence of adverse consequences of substance 
misuse, including OUD, through early intervention and, when needed, referral to treatment. 
SBIRT can be used as a preventative approach by targeting individuals with non-dependent 
substance use, and is an effective strategy to intervene prior to the need for more extensive or 
specialized treatment.29 
  To determine appropriate steps for cancer survivors and their pain management, our 
proposal is to implement a clinic change process to include the Screening, Brief Intervention, and 
Referral to Treatment intervention during cancer survivors’ follow-up appointments. SBIRT is 
an evidence-based public health program sponsored by the US Substance Abuse and Mental 
Health Services Administration, Center for Substance Abuse Treatment (SAMHSA, CSAT) to 
“identify, reduce, and prevent problematic use, abuse, and dependence” on alcohol and tobacco, 
and is being expanded to illicit and prescription drugs.25,30  
  SBIRT begins with a rapid assessment of substance use, then utilizes motivational 
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interviewing techniques to assess a patient’s stage of change, as described in the Transtheoretical 
Model of Change (pre-contemplation, contemplation, preparation, action, maintenance and 
termination), and then performs a brief intervention.29,31 Motivational interviewing is a style of 
counseling that guides participants to realize their personal goals, and helps to resolve 
ambivalence that prevents them from reaching their goals by improving self-efficacy. The five 
principles of motivational interviewing include: 1) Express empathy through reflective listening; 
2) Develop discrepancy between clients' goals or values and their current behavior; 3) Avoid 
argument and direct confrontation; 4) Adjust to client resistance rather than opposing it directly; 
5) Support self-efficacy and optimism.32 On an interpersonal level of the Socio-Ecological 
Model, the goal is to assist the patient in becoming more aware of their potentially problematic 
behaviors, motivate them to change, and then refer them to a specialist. 33,34   
  The intervention will take place in three clinics at Markey Cancer Center that focus on 
the following cancers: breast, prostate, and melanoma/skin. These particular cancer types were 
chosen because they have over a 90% 5-year relative survival rate, and were three of the four 
most common cancer sites treated at Markey in 2018.35,36 Due to the high patient volume in these 
clinics, the investigative team suspects there will more likely be a subset of the population with 
either a past history or future risk of opioid misuse or dependence. Clinic volume figures and 
sample size calculation can be found in Appendix C. We will assess future risk of dependence by 
having participants complete the Screener and Opioid Assessment for Patients with Pain 
(SOAPP) Version 1.0-14Q, and utilize the Current Opioid Misuse Measure (COMM) during 
follow-up appointments to assess misuse and determine need for a brief intervention. 
 Evidence Base of Screening, Brief Intervention, and Referral to Treatment (SBIRT)  
  In 1980, the World Health Organization made a call to the scientific world to improve 
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treatment and diagnosis of people with hazardous alcohol use. The initial program of Screening 
and Brief Intervention was developed at this time, and ultimately developing the Alcohol Use 
Disorders Identification Test (AUDIT), which is now the most widely used evidence-based 
alcohol screening test in the world. A decade later, the program was expanded to include the 
Referral to Treatment component and has been applied in various settings across the globe. 
SAMHSA funded three cross‐site evaluations to provide an independent, systematic examination 
of its SBIRT programs to determine whether the grant program had achieved its intended 
outcomes. The evaluation included two cohorts of grant recipients, totaling 11 programs, and 
described in terms of the SBIRT service components, performance sites, providers, management 
structure/activities and patient/client characteristics. In 2004, SAMHSA investigated the first 
cohort of SBIRT grant awardees, with the second cohort’s evaluation taking place in 2009. As of 
2017, the third cross-site evaluation was underway for the grant awardees in 2013 and 2014.  
Overall, the evaluations found the program was effective in its’ intended outcomes, which was 
consistent with previously published research.37  
  To further investigate the strength of the evidence-base of SBIRT, an overall review was 
conducted, analyzing six meta-analyses of randomized clinical trials and one systematic review 
on non-alcoholic alcohol drinkers. The review reported that 5 of 7 studies found a moderate 
decrease in consumption, and 4 of 7 studies experienced a significant decrease in the number of 
participants who continued to use alcohol. The review also determined that a brief 15-minute 
intervention at multiple points of manifests lasting effects that persist for at least 6 months.38 
This supports SBIRT’s claim that the program is effective in preventing problematic use, and is 
not only for those who have already developed a substance use disorder. 
  SBIRT is effective in a wide range of settings including emergency rooms, primary care 
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clinics, and community settings. Additionally, the SBIRT framework is valid to use for 
adolescents, adults, and seniors. The screening component has found to be effective in a variety 
of modalities including telephone, paper, online, and physician administered. The flexibility and 
validity of this framework for tobacco and alcohol use in various settings, populations, and 
modalities gives strong support for the success of employing this method for prescription 
medications, such as opioids.34  Additionally, motivational interviewing has been found to be 
effective in chronic pain populations wishing to taper their opioid dose.39 
    In March of 2019, several medical doctors at Yale University conducted a randomized 
controlled trial using an adapted SBIRT-Pain Module (SBIRT-PM) that they had created to 
effectively screen for substance use disorders in veterans with chronic pain stemming from 
musculoskeletal disorders. The trial had three arms at a 2:1:1 randomization ratio: SBIRT-PM 
with counselling, Pain Module counseling only, or standard of care without counselling.  Those 
who were randomized to the counselling conditions were significantly more likely to fulfill 
service referrals and make changes to their pain management plan. Participants in SBIRT-PM 
were significantly less likely to use substances over time (β = –0.13, P = 0.015, d = –0.84). The 
standard of care group were more likely to withdrawal from the study at week 12 (32% vs 12% 
and 11%, respectively; P < 0.05). Ultimately, SBIRT-PM showed promise as a way to engage 
veterans in pain treatment and reduce substance use, and provides evidence that SBIRT can 
effectively be used in a chronic pain population.40     
Adaptations 
 SBIRT has been shown to be effective in a variety of settings but have primarily focused 
on tobacco and alcohol use, and has limited its focus to non-cancer pain populations.  The first 
major adaptation in this intervention is using SBIRT in a cancer survivorship population with 
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cancer-related pain, who may also experience chronic pain. The second major adaptation to this 
intervention is using SBIRT for prescription opioid dependence.  Currently, the effectiveness of 
SBIRT in cancer pain populations or in populations with prescription opioid dependence are 
unknown. Minor adaptations include using screening tools that will be used to assess need for 
risk monitoring and for assessment of opioid misuse, abuse, and dependence.  The major 
adaptations of this intervention are essential to addressing opioid dependence in cancer 
survivors.  In light of the opioid epidemic, it is now more important than ever to ensure that 
oncologists are confident in their opioid prescribing practices for their patients, and that patients 
are satisfied with their pain management treatment course.  Anecdotal evidence shows that 
providers are already using SBIRT and motivational interviewing techniques to address opioid 
use in cancer patients.  To date, there have not been any studies targeting this vulnerable 
population specifically with the SBIRT methodology.  
Education, Stigma Reduction, Claims 
 There are major challenges regarding stigma reduction towards people who have cancer, 
people who receive opioid prescriptions, and those who have or are at risk of developing an 
OUD.   It is important to remember that the goal of this program is to improve the cancer 
survivorship experience by identifying whether individual patients are best served by opioids for 
managing their pain; not to unnecessarily take away their medications. There are some cancer 
survivors who will have severe chronic pain for the rest of their lives and may need to be on 
some level of opioids during that time.41,42 Cancer patients experience substantial pain from their 
treatments, and deserve to have that pain treated without feeling as though their provider or clinic 
staff is judging them for continuing to take opioid prescriptions. On the other side of the lens, 
providers understand how painful cancer can be, so they may not be concerned about a cancer 
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patient’s opioid prescriptions, and be unaware of whether opioids may be inciting more harm 
than help.  
  There is strong evidence that educational anti-stigma interventions are successful in 
reducing stigma.21,22,43 Our education plans for the clinic providers and staff regarding cancer 
pain will include the full spectrum of cancer treatment side effects, their correlation with pain, 
and appropriate pain management plans. To reduce stigma related to opioids, our education plans 
will focus on the neurological and physiological changes that happen after taking opioids for an 
extended period of time. This is essential for clinic staff to understand the underlying 
mechanisms that drive resistance to opioid reduction and cessation. By educating the clinic staff 
in this aspect, it will help them to understand from a biological level what is happening with their 
patients, and that it is not merely a moral failing or lack of motivation.  Lastly, we will build 
providers confidence in their ability to prescribe the appropriate amount of opioids to their 
patients without needing to worry about contributing to the opioid epidemic.  
Sustainability 
  This intervention is intended to be a clinic process change. We are intentionally designing 
this project to have the clinic staff provide and score the initial risk monitoring tool (SOAPP) to 
the participant, and then informing the provider of their score and whether they qualify for a 
brief intervention, rather than assigning these tasks to behavioral research associates whom will 
no longer be involved in the process after the grant ends.  While there are still areas that can fail 
post-project period, our intention is that the screening mechanisms will become standard 
operating procedures embedded into the clinic workflow beyond the funding cycle of the grant. 
Our activities of providing the training to conduct the FMEA, intensive training with PDSA-
cycle worksheets, and implementing the practice management specialist support this aim. 
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Additionally, the clinic champions will also receive motivational interviewing training to help 
them navigate resistance within the clinic staff and hold providers accountable to their training. 
  If our program is found to be implemented appropriately, as determined by the process 
evaluation and the outcome evaluation, the data from this project will allow the institution to 
secure funding from SAMSHA to provide an expanded, formal SBIRT training program for 
providers.  Securing additional funding will further disseminate SBIRT implementation, 
resulting in an overall cultural change in the institution.  We will communicate our study results 
via the MCCAN and MCCRN networks, UK Healthcare, and to the CAG, partners, and 
stakeholders through roundtable discussions, presentations, conference attendance, and others as 
deemed appropriate.  
Inclusivity and Appropriateness for the Population 
  To ensure that all program materials are medically accurate, inclusive, and culturally and 
linguistically appropriate, we will use nationally recognized evidence-based guidelines and 
educational materials from the CAIPEC resources.  We will submit materials that will be viewed 
by our participants to the Human Development Institute (HDI) at the University of Kentucky to 
assist in identifying any needed modifications. The Human Development Institute’s website 
states that their mission is, “To promote the inclusion, independence, and contributions of people 
with disabilities and their families throughout the lifespan.  We achieve our mission through 
education, research and evaluation, information sharing, leadership, and advocacy across 
Kentucky and the nation.”44  As a final reviewing team, we will employ our Community 
Advisory Group to review all materials to ensure that our material messages will be received in 
the way that they are intended. 
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 To address any concerns the participants may have during their participation, we will 
supply several avenues for them to submit claims. The University of Kentucky Office of 
Research Integrity website states that, “It is IRB policy that a safe confidential, and reliable 
channel for current, prospective, or past research participants, their representatives or others, is 
provided that permits them to discuss problems, concerns, and questions; obtain information; or 
offer input with an informed individual who is unaffiliated with the specific research protocol.  
Each IRB approved informed consent document includes the ORI Research Compliance 
Officer's toll-free phone number (1-866-400-9428) as a subject's primary contact point for this 
purpose.”45  Additionally, they will be given contact information for the primary investigators 
and research coordinator to submit concerns and claims. Lastly, the research staff will directly 
address the potential for these issues by directly asking participants at the end of their 
participation whether they had any concerns about their participation. 
Recruitment and Retention 
 For an effective intervention, we will need to have a recruitment and retention plan for 
both the clinics and the patient participants.  Clinic recruitment and retention is essential to the 
success of this intervention and requires a champion to ensure that the intervention is maintained 
in the workflow.  Potential clinic champions and physicians have been recruited by utilizing a 
mutual acquaintance in the cancer center to establish an interpersonal relationship.  The research 
team met with each clinic team to explain the purpose of the study and why their particular clinic 
was chosen as a potential participant. Clinic champions and physicians will be monetarily 
compensated for their time at an appropriate rate to ensure that they are satisfied with the 
additional steps in the clinic workflow.  To encourage clinic retention, the clinics will have 
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monthly challenge rewards for those who completed the most screenings and had the most 
successfully completed referrals.  
 To recruit participants, study personnel will conduct the screening of potential 
participants, and inform the clinic staff of which people should be approached. The clinic staff 
will insert the research study consent form into their intake packet, to be reviewed while they are 
waiting for their appointment. Study personnel will review the study protocol, including referral 
to treatment options, and consent form with the patient. If willing to participate, the study 
personnel will obtain a signed informed consent and provide a copy to the participant. 
Compensation for the participants’ time will include an initial $5 for completing the initial risk 
monitoring survey, provided to the participants and scored by the clinic staff, who will then 
inform both the study personnel and clinic provider on whether they are mild, moderate, or 
severe risk for dependence. To retain participants, the follow-up surveys will be completed 
during their regularly scheduled follow-up appointments. To compensate for their time, 
participants will receive $5 for each follow-up survey completed, totaling $15. If the participant 
completes all three follow-up surveys, the will receive an additional $15 at the completion of the 
study participation. This type of payment schedule is an acceptable standard in substance use 
populations for maximum retention, and the payment amounts are deemed low enough to prevent 
unintended coercion. 
  Since our target population is very specific and medically frail, we expect to have some 
difficulty with recruitment into the study. To assist in determining what changes need to be made 
in our recruitment strategy, we will ask eligible participants why they declined or agreed to 
participate. We will provide a set of responses in checklist format with an option for “other” to 
reduce burden on those who agree to answer. The responses will be determined by the focus 
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group prior to the beginning of the study and modified based on frequent fill-in responses from 
the “other” category. 
Monitoring and Fidelity 
  Please see the Process Evaluation section of this proposal provides detailed information 
on how the sites will be monitored. To ensure fidelity and loyalty to the proposal, we are 
providing a $20,000 clinic stipend to increase buy-in from the staff by providing protected time 
for them to conduct the study. We will also identify a champion in each of the three clinics who 
will enthusiastically commit to the protocol and purpose of the study.  
  A 6-month readiness period for the implementation of the study will be employed to 
allow for an adjustment period. The readiness period will give the clinics an opportunity to get 
comfortable with motivational interviewing techniques before deploying in the research setting. 
During the first three months of the readiness period, providers and clinic champions will be 
trained in motivational interviewing techniques using resources provided by SAMSHA. “A Tour 
Motivational Interviewing: An Interprofessional Road Map for Behavior Change” is a free, self-
paced online course provided by SAMSHA, and was prepared by the University of Missouri 
Kansas City School of Nursing and Health Studies’ Mid-America Addiction Technology 
Transfer Center.46  Additionally, they will be provided with an "MI Reminder Card (Am I Doing 
This Right?),” a pocket card reference guide to take with them in the clinic. The 11 questions on 
this card assist in building self-awareness about the interventionists’ attitudes, thoughts, and 
communication style as they work.46 The providers and champions will give a mock motivational 
interviewing intervention with a non-trained clinic staff worker each month. Both the clinic staff 
worker and the trainee will be given a case scenario for the ‘patient’ to act out. The mock 
intervention will be video recorded in order to reduce the Hawthorne Effect, and then observed 
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and scored by the Oncology Social Work trainer, who will grade the interaction based on the 
training manual standards. The trainee will be asked to view their interaction and grade 
themselves, then a meeting will take place to identify areas of improvement and conduct 
refresher training.  Please refer to the Process Evaluation section for metrics that will be 
measured.  
Challenges and Risks 
 Clinic-based research studies, such as this proposal, face unique challenges due to the 
setting. The most difficult challenge is that medical clinics are already exceptionally busy, 
severely limiting available time to identify eligible participants and conduct research. We will 
employ a Practice Management Specialist to find time savings in the clinic, as well as a Clinic 
Task Force to help ensure that the participant and provider have enough time in the clinic to 
complete the study materials, and maintain the integrity of the protocol as written within the 
clinic workflow. We will also provide a clinic stipend as an incentive for the clinics to assist in 
holding themselves accountable to maintain the research project. Buy-in from providers and 
clinic staff is essential to the success of this project.  Another major challenge is that our 
providers cannot be blinded to the intervention, meaning that they may unintentionally bias 
results. Additionally, the providers may begin using the techniques and screening measures 
they’ve acquired during the study when interacting with other patients who are not enrolled.  
 The risks for patients to participate in this study are minimal and do not exceed the risks 
encountered in everyday life.  Some questions on the study measures may be of sensitive nature 
and uncomfortable for some participants to answer.  All participant contribution is voluntary, 
participants are allowed to skip any questions that they do not want to answer and can 
discontinue their participation at any time.  Patient materials will be de-identified and coded with 
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a unique participant code and will follow the UK Standard Operating Procedures to maintain 
HIPAA compliance and Good Clinical Practice guidelines. 
PERFORMANCE MEASURES AND EVALUATION 
 This proposal will use a stepped-wedge study design, also known as a phased 
implementation, with each clinic serving as its own control.  To measure whether the 
intervention is effective and not due to external factors, we will compare baseline counts for the 
outcome measures versus post-implementation counts.  We will “Go-Live” in Clinic 1 during 
Year 1, month 7; Clinic 2 in month 9; and Clinic 3 in month 11. This will provide two months of 
data collection in each clinic, and an opportunity to improve the intervention before deploying in 
the next clinic. This timeframe also allows to have two months of implementation in Clinic 3 
before the beginning of Year 2 of the project. This design is ideal from an ethical standpoint: this 
is a high-risk population and it is imperative that all eligible participants receive the intervention. 
More information on Study Design, Eligibility, and Sample Size can be found in Appendix C.  
  The first measure we will administer to participants is the Screener and Opioid 
Assessment for Patients with Pain (SOAPP) Version 1.0-14Q and is meant to be completed 
before a patient is placed on a long-term opioid therapy, when a pain management plan is 
established.47 See Appendix D for full instrument, and Table 3 for cutoff score information. This 
tool is designed to assist clinicians in determining how much monitoring a patient on long-term 
opioid therapy will likely require and takes approximately 8 minutes to complete. It is essential 
to ensure that cancer survivors have adequate chronic pain management because all people 
deserve to be as pain-free as possible. In light of the opioid crisis, many practitioners are hesitant 
to prescribe opioids,42 and this tool helps to clarify concerns.  
  One important, yet often overlooked, aspect of the COMM tool is that it addresses family 
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history of substance abuse and whether the patient has ever had their medications lost or stolen, 
which can be an indicator to educate patients on proper opioid storage at home.48 This item is 
imperative because in Kentucky, of those who use prescription opioids non-medically for more 
than 200 days per year, 27% use their own prescriptions; 26% are given them by friends or 
relatives; 23% buy opioids from friends or relatives; and only 15% buy from a drug dealer.49  
Since the prescribing rates in the south eastern and south western parts of KY are much higher 
than the central part of the state, our research team and providers will need to be proactive in 
addressing shared prescriptions.  If a participant from a high-risk area indicates that they have 
had prescriptions lost or stolen, or friends or family with substance abuse disorders, our 
providers will take special care to address this during the motivational interviewing intervention.  
 Sensitivity Specificity Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Positive 
Likelihood 
Ratio 
Negative 
Likelihood 
Ratio 
SOAPP        
Score 7 or above .91 .69 .71 .90 2.92 .13 
Score 8 or above .86 .73 .75 .86 3.19 .19 
Score 9 or above .77 .80 .77 .80 3.90 .28 
COMM       
Score 9 or above .77 .66 .66 .95 2.26 .35 
   The second measure we will administer to participants is the Current Opioid Misuse 
Measure (COMM), a 17-item self-report instrument designed to monitor a chronic pain patient's 
use of opioids and assess misuse by asking about social, emotional, and functional problems and 
behaviors related to prescription medication misuse.50 See Appendix E for full instrument. The 
COMM will be administered during the 3 month, 6 month and 12 month follow-up 
appointments. Follow-up timelines vary dramatically depending on the type of cancer, location, 
and treatments (radiation, chemotherapy, surgery), however it is standard at minimum to have a 
3, 6, and 12 month follow-up appointment.  Regarding the construct validity of the instrument, 
Table 3. SOAPP and COMM Cutoff Scores 
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Meltzer et al. found higher COMM scores in patients with chronic pain who had a prescription 
drug use disorder than in those who did not have the disorder.51 Table 4 below shows the 
psychometric properties associated with our validated measures, including the Opioid Therapy 
Provider Survey (OTS), which is used in the Process Evaluation. 
  
Both the SOAPP and COMM measures take less than 10-minutes to complete and are self-
reported, making it practical for the patient to complete during their clinic visits without 
significant disruption of the clinic workflow. Additionally, both measures use the same scoring 
methods, by summing the individual question scores to calculate the overall total score. Using 
similar scoring mechanisms will reduce the need for additional training. 
Table 4. Validity of Measures 
Construct Psychometric Properties 
Prediction of 
Need for 
Opioid Risk 
Monitoring 
Screener and Opioid Assessment for Patients with Pain (SOAPP) Version 1.0-14Q. 
The 14-item survey is scored on a 5-point Likert scale.  Chronbach’s alpha was 
calculated for initial SOAPP results (N=175) and for follow-up retest (N=95), 
achieving a=0.74 for both samples.47 Negative Predictive Value for a cutoff score of 7 
is .90; score of 8 is 0.86, and score of 9 is 0.80. Despite its’ intention to capture as 
many people as possible, leading to many false positives, a person with a positive 
SOAPP score at the cutoff of 7 is 2.94 times as likely to be someone who is actually at 
high risk; scores of 8 are 3.19 times as likely; scores of 9 are 3.90 times as likely. 
Opioid Misuse 
Assessment 
Current Opioid Misuse Measure (COMM). This tool is intentionally designed to over-
identify misuse, rather than failing to identify those at high risk (PPV = 0.66, NPV = 
0.95). A study published in the Clinical Journal of Pain examined the validity and 
reliability of the COMM against the Aberrant Drug Behavior Index (ADBI), finding 
the internal consistency for cross validation to be excellent with a = 0.83, compared to 
a = 0.86 in the original study.  The receiver operating characteristic curve (ROC) 
analysis yielded an area under the ROC (AUC) of 0.79 (Standard error = .031; 95% CI: 
.74 to 86; p < .001).50 
Pain Levels FACES Pain Scale. A study comparing four pain scales in children ages 3-18 found the 
FACES Pain Scale to be valid and reliable: a = .60, r = .74. There were no significant 
differences in validity or reliability across all four measures. 
Provider 
confidence in 
prescribing 
opioids 
Opioid Therapy Provider Survey (OTS). The 10-item survey is scored on a 5-point 
Likert scale, where 1= strongly agree and 5= strongly disagree.52  All items were based 
on an extensive literature review, then developed through consensus among researchers 
with over 20 years averaged experience with chronic pain patients.  Content validity 
was initially established through item examination for missing data and respondent 
comments and reliability was judged to be suitable (Cronbach's alpha = 0.28).53 
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   Patient satisfaction and ability to manage pain will be measured by using a self-report 
survey at each encounter, as seen in Tables 5. These items will be developed with assistance 
from the Behavioral Research Assistant. 
Property Verbiage Scoring 
Patient Satisfaction “How satisfied are you with 
your pain treatment?” 
5-point Likert scale (1 = Extremely 
Dissatisfied to 5 = Extremely Satisfied) 
Pain Management “How well are you able to 
manage your pain?” 
5-point Likert scale (1 = Extremely 
Dissatisfied to 5 = Extremely Satisfied) 
 
  To measure pain levels, we will use the Wong-Baker FACES Pain Rating Scale (0 = No 
Hurt, 10 = Hurts Worst) as 
seen in Figure 2.54  
Physical functionality will 
be measured using 
assessments provided in 
the CAIPEC toolkit.     Figure 2. Wong Baker FACES Pain Rating Scale54 
Process Evaluation 
 The process evaluation for this program will be closely tied with the project management 
plan to ensure that we are implementing the project according to the project schedule and 
reaching the goals of the program. A Failure Modes and Effects Analysis (FMEA) will be 
conducted several times during the project by the Clinic Task Force, as seen in the Gantt Chart, 
specifically during the last 3 months of the readiness period (Year 1 Q2), during the first 6 
months post-Go-Live (Year 1 Q3, Q4) and then at Year 2 Q1 and Q4. To conduct the FMEA, we 
will assess the following: 1) Steps in the process 2) Failure Modes (What could go wrong?) 3) 
Failure Causes (Why would the failure happen?) 4) Failure Effects (What would be the 
Table 5.  Patient Perspective Measures 
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consequences of each failure?).55 We will use a team approach to modify the protocol to address 
the concerns. During the lifetime of the project, we will track the identified FMEA aspects 
during the project with our PDSA cycle worksheets. Table 6 below outlines the process 
evaluation metrics that will measured to ensure proper provider education to support successful 
implementation and execution. 
  
  The metrics for rate of opioids prescribed and number of referrals given and filled will be 
extracted from the Electronic Health Record.  Physical functionality and FACES scale numbers 
will be inserted into the Electronic Health Record as well to improve sustainability and 
adherence to the protocol. To measure the providers’ knowledge of guidelines for cancer pain 
patients and knowledge of alternative therapies for appropriate types of pain available at UK, we 
will conduct a pre-test prior to education and training during the readiness period. Since 
availability of therapies are location-specific, we will need to modify existing measures provided 
in the CAIPEC toolkit.   
   To identify key successes, challenges, and lessons learned, we will conduct key 
informant interviews every month with the providers, clinic staff, and project staff.  The topics of 
conversation in the interviews will begin with reviewing the PDSA cycle worksheets and how 
they have aligned with the pre-project FMEA analysis. We will also review metrics that we have 
Table 6. Process Evaluation Metrics for Providers 
1) Quiz scores on SBIRT and educational trainings including: 
a. Provider knowledge of guidelines for cancer pain patients and opioid prescribing 
b. Knowledge of palliative care alternative therapies for appropriate types of pain  
c. Confidence in prescribing opioids (OTS Survey) 
2) Motivational interviewing performance 
3) Number of physical functionality assessments completed  
4) Number of opioid monitoring measures given 
5) The number of referrals given for alternative therapies 
6) Number of FACES pain scales administered 
7) Rate of opioid prescriptions 
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collected during the project, specifically the recruitment strategies, recruitment numbers, number 
of referrals given and completed, counts of major and minor protocol deviations, patient 
satisfaction, etc.  The interviews will allow the team to provide their input as executors of the 
protocol and study impact, while providing confidentiality.  We have elected key informant 
interviews rather than focus groups to offset group-think about how well the intervention is 
working. Additionally, key informant interviews provide the opportunity to receive more 
detailed feedback about how the providers, clinic staff, and other project staff are performing and 
interacting with participants without risking fear of retaliation.  
Outcome Evaluation 
  To assess the impact of the SBIRT intervention and determine the extent to which the 
outcome goals were met by the program and not due to chance or external factors, we will 
compare baseline metrics to post-implementation metrics.  Output metrics for the participant are 
listed in Table 7. 
CAPACITY OF APPLICANT ORGANIZATION 
  The University of Kentucky is categorized as a Research Intensive Institution that has 
extensive experience in implementing evidence-based programs on a large scale, as well as 
implementing projects in the communities. Research and academic activity at the University of 
Kentucky (UK) spans all 16 colleges, the Graduate School (including the James W. Martin 
School of Public Policy and Administration and the Patterson School of Diplomacy and 
Table 7. Outcome Metrics for Participants  
1) Satisfaction with pain treatment  
2) Ability to manage pain  
3) Scores on opioid monitoring measures (SOAPP and COMM scales) 
4) Number of opioid monitoring measures completed 
5) Number of referrals to palliative care or alternative therapies completed by the patient. 
6) Rate of opioid prescriptions 
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International Commerce), some 80 multidisciplinary research centers, and 30 core research 
facilities. UK is one of 115 private and public universities in the country to be classified by the 
Carnegie Foundation for the Advancement of Teaching among Doctoral Universities: Very High 
Research Activity (R1) in 2018. R1 universities represent 2.5% of all institutions in the 
classification system. UK faculty, staff, and students brought in more than $417.1 million in new 
sponsored project awards in FY 2019. Of that total, UK was awarded $241.8 million in grants 
and contracts from federal agencies. 
  In regards to substance misuse and abuse, UK is home to the Center for Drug Abuse 
Research, which facilitates the largest research grant ever received by the University of 
Kentucky, NIH’s HEALing (Helping End Addiction Long Term) Communities Study. The 
HEALing Communities Study is a four-year, $87 million study aimed at reducing opioid 
overdose deaths by 40 percent, and was developed by researchers from UK spanning six 
colleges, in partnership with state leaders. As one of four sites nationwide, UK and the 
Commonwealth of Kentucky will address the opioid epidemic in a randomized study that 
includes 16 Kentucky counties acutely impacted by opioid abuse. The study will leverage 
existing resources and initiatives, in partnership with communities, to implement strategies and 
set evidence-based standards that will become a national model for fighting the opioid epidemic. 
  As the only NCI-designated cancer center in Kentucky, MCC's mission is to reduce 
cancer mortality through a comprehensive program of cancer research, treatment, education, and 
community engagement with a particular focus on the underserved Appalachian population of 
eastern Kentucky. Since UK MCC is so robust, it hosts its’ own business office to manage 
financial resources, interfacing closely with the main campus Accounts Payable and Payroll 
departments. According to the 2018 Annual Report, MCC is driven by 235 research projects 
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representing more than $41 million in research, with 2.7 million dedicated to education and 
research training. The MCC treats nearly 3,400 new cancer patients and over 8,000 returning 
cancer patients and survivors annually at the Chandler Medical Center.36   
  MCC has a substantial community partnerships across the state of Kentucky MCC’s 
MCCAN and MCCRN sites extend into Appalachia and surrounding regions at 22 separate 
facilities with a shared vision of increased access and delivery of high-quality cancer care, and 
clinical trials. A new collaboration, UK Markey Cancer Center at Lexington Clinic will enhance 
and expand outpatient cancer care throughout Central Kentucky.   
  The University of Kentucky is home to extensive quality improvement initiatives, 
ranging from clinical care to research to administration. UK HealthCare delivers high-quality 
continuing professional development activities to physicians, pharmacists, and other health care 
professionals via the CECentral platform, which functions as a full-service continuing education 
(CE) solution for healthcare professionals. To manage staff performance, UK uses enterprise 
services for annual performance reviews, time entry, and paid leave.     
  The University of Kentucky is committed to a diverse and inclusive workforce that 
strives to foster a community where people regardless of sex, race, ethnicity, religion, age, 
ability, sexual orientation, or gender identity, can feel secure and welcome. In the interest of 
maintaining a safe and healthy environment for our students, employees, patients and visitors the 
University of Kentucky is a Tobacco & Drug Free campus. As an Equal Opportunity Employer, 
we strongly encourage veterans, individuals with disabilities, women, and all minorities to 
consider our employment opportunities. 
PROJECT MANAGEMENT 
  The project management plan below describes how the project will be implemented, 
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managed, and monitored. See Appendix F for the Logic Model and Appendix G for the Gantt 
Chart, detailing activities during the 3 year project period, including plans for FMEA analysis 
and PDSA-cycle worksheets. Once the project reaches the “Go-Live” stage, we will use “Plan-
Do-Study-Act” (PDSA) worksheets to delineate areas of improvement for our program, found in 
Appendix H.  We will determine our initial approach and set a goal number for the appropriate 
activities, such as participant accrual. During the initial 3 months post-Go-Live, we will ‘study’ 
the approach and the accrued metrics on a bi-weekly basis before making minor changes for the 
second round of the PDSA cycle.  A bi-weekly cycle schedule is ideal, since it is long enough to 
allow enough time for changes to gain traction but short enough to prevent major issues to go 
unnoticed.  During months 5-12, we will continually assess the study progress to address 
significant changes that need to be made, such as changes in clinic workflow, refresher training 
for project staff, changes in data collection or management processes, participant recruitment and 
attrition, and others. By the end of year 1, we expect to have solidified and stabilized all aspects 
of the protocol to run smoothly through years 2 and 3. We plan to conduct interim statistical 
analysis every 6 months to monitor impact. 
Project Management: Team Responsibilities 
See Appendix I for the Organizational Chart, outlining personnel reporting lines. 
Title Responsibilities 
Primary 
Investigator 
 
1) Provide consultation to clinics and act as final authority on workflow changes 
2) Review high-level progress reports of the project to ensure milestones are being 
met in accordance with the funding sponsor’s guidelines 
3) Review potential participants’ screening files and approve enrollment 
4) Assist in hiring and termination of key staff 
5) Act as the emergency contact for Adverse Events and Serious Adverse Events. 
6) Disseminate findings to CAG, Partners, and Stakeholders.  
Project 
Director 
 
1) Develop, monitor, and make any necessary changes to the research protocol, 
budget, process evaluation, staff scheduling, IRB continuation review 
submissions, research participant payments, and other administrative activities as 
deemed necessary.  
Table 8. Project Management: Team Responsibilities 
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2) Identify and interview key project staff. Supervise all project staff. Ensure proper 
trainings have been completed by all research staff, clinic personnel, and clinic 
providers. Assess professional development needs; provide at minimum annual 
professional development opportunities for research staff and semi-annual 
opportunities as deemed necessary.  
3) Engage the Community Advisory Group 
4) Report Adverse Events and Serious Adverse Events to the appropriate authorities 
on the appropriate timelines. 
Clinic 
Providers 
 
1) Central point of contact between participants and research team. 
2) Conduct motivational interviewing techniques to improve likelihood that a 
participant will agree to reducing opioid prescriptions and follow through with 
referrals.  
3) Provide referrals to alternative therapies for participants. 
4) Provide brief report of interactions with participants to clinic staff, to be passed 
off to Behavioral Research Associates for documentation. 
Oncology 
Social Workers 
 
1) Provide sensitivity and motivational interviewing trainings to clinic providers. 
Track education and trainings for all clinic personnel and report to Project 
Director. 
2) Assist in patient navigation to schedule their referral appointments, arranging 
transportation to/from the clinics, etc. 
3) Coordinate with Behavioral Research Associates to ensure all participant materials 
and data are available and entered according to project timelines. 
4) Act as mediator for tension between providers, clinic staff, and participants.  
Behavioral 
Research 
Associates 
 
1) Reviewing Electronic Medical Record data to identify eligible patients for 
recruitment 
2) Approaching patients in the clinic to recruit into the study, completed all screening 
and consent procedures. Ensure protocol materials have been complete and 
returned by clinic staff.  
3) Provide participant payments. 
4) Review all data collection and ensure procedures have been followed according to 
Good Clinical Practice Guidelines. 
5) Enter paper-based survey data. Conduct minor data management as needed.   
6) Provide administrative services such as putting together materials for participant 
screening files, creating participant calendar schedules, tracking demographic 
metrics for IRB continuation review reporting, etc.  
Biostatistician 
 
1) Develop study design 
2) Conduct sample size and power calculations 
3) Conduct preliminary, intermediary, and final data analysis 
4) Conduct major data management as needed 
5) Provide data interpretation summaries and figures for presentations, publications, 
future grant proposals, etc. 
Practice 
Management 
Specialist 
 
1) Identify places in clinic workflow to find time-savings in order to insert research 
protocol without increasing required clinic time for the study. 
2) Conduct the Failure Modes and Effects Analysis. 
Clinic Task 
Force 
 
1) Ensure proper implementation of the study into the clinic workflow to increase 
sustainability after the project grant funding ends.  
2) Track progress of Failure Modes Effects Analysis and Plan, Do, Study, Act 
worksheets.  
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Clinic Staff  1) Coordinate with the behavioral research associates to ensure that identified 
participants who are potentially eligible for the study are screened, and if eligible, 
consented.  
2) Distributed the SOAPP and COMM scales to the participants.  
3) Score SOAPP and COMM scales, communicate to provider whether a brief 
intervention or referral to treatment is needed.  
4) Provide completed SOAPP and COMM scales to the Behavioral Research 
Associates, along with all reports from the provider.  
5) Contact Oncology Social Work team to assist with patient navigation. 
 
PARTNERSHIPS AND COLLABORATION 
  Our stakeholders and partners are entities that are imperative to the successful 
implementation of the proposed project. We have identified groups from a national, state-wide, 
and the local community level to ensure comprehensive representation, seen in Table 9. We have 
obtained letters of support for all entities listed below.  Effective two-way communication with 
stakeholders and partners is essential to the success of this project. Our Primary Investigator and 
Project Director will be the central points of contact for all communications. We will disseminate 
a quarterly newsletter to local entities, host bi-annual meetings with local and state entities, and 
provide a bi-annual report to local, state, and national level groups. 
Entity Level Role 
American College of Surgeons - 
Commission on Cancer 
National A consortium of professional organizations 
dedicated to improving survival and quality of life 
for cancer patients through standard setting, which 
promotes cancer prevention, research, education, 
and monitoring of comprehensive quality care. 
American Society of Clinical 
Oncology 
National Diverse network of nearly 45,000 oncology 
professionals dedicated to providing the highest-
quality resources in education, policy, the 
pioneering of clinical research, and advancing 
cancer care. 
US Department of Health and Human 
Services 
National The largest biomedical research agencies in the 
world. Made of 27 Institutes and Centers, 
including the NIH, NIDA, NCI, and SAMHSA 
Kentucky Injury Prevention and 
Research Center (KIPRC) 
State Partnership between UK and Kentucky Dept. for 
Public Health. Works to reduce injury through 
education, policy initiatives, public health 
programming, surveillance, risk factor analysis, 
Table 9. Stakeholders and Community Partnerships 
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direct interventions, and evaluation. Hosts 
findhelpnowky.org.  
Kentucky All Schedule Prescription 
Electronic Reporting (KASPER) 
State Controlled substance prescription monitoring 
system, tracks prescriptions per person to assist 
medical personnel in decision-making.  
Lexington Fayette Urban County 
Government and Health Department 
Local Performs essential functions such as providing 
police protection, administrating health and 
welfare services, keeping records, establishing 
policies and laws.   
Local Lexington Hospitals: St. Joseph 
Health, Baptist Health, Lexington VA 
Medical Center, The Ridge Behavioral 
Health System, Eastern State Hospital 
Local Provide medical services to Kentucky residents. 
Stakeholders who have a vested interest in the 
opioid epidemic, cancer treatment, and quality 
improvement initiatives. 
   
UK Office of the Vice President for 
Research 
Research Major research entity at UK; provides oversight 
and guidance of 13 multidisciplinary research 
centers, including MCC and CCTS 
UK Center for Drug Abuse Research Research Conducts research into the biological, 
psychological, sociopolitical, and clinical aspects 
of substance abuse and related behavior. Provides 
consultations to public agencies and state and local 
government 
UK College of Medicine Clinical 
& 
Research 
Provide medical services to Kentucky residents, 
ensuring best practices are being followed.  Major 
drivers for implementation of new research 
findings. These entities are directly involved in this 
grant proposal and will be represented when 
disseminating findings to other groups.  
UK Healthcare Clinical 
UK Interventional Pain Associates Clinical 
UK Healthcare Palliative Care Team Clinical 
 
 
Community Advisory Group 
   We will establish a Community Advisory Group specifically regarding opioid misuse in 
cancer survivors. The Primary Investigator of this project has identified 7 main areas to obtain 
representation, and will host bi-annual meetings to discuss barriers to implementation, challenges 
with clinic work flow, recruitment and retention, and other challenges in addition to the 
communications with stakeholders and partners mentioned above.  To recruit these individuals, 
the Primary Investigator will reach out to the organizations by prioritizing those of which they 
already have established connections. For those that do not have an established network, the PI 
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will directly contact the organizations to request a meeting consultation. All individuals will be 
compensated monetarily for their time on the CAG.  The Community Advisory Group will 
ideally be comprised of individuals from the organizations in Table 10.  
Markey Cancer Center Affiliate 
Network  
John Lennon, Director Dissemination of programs across 
MCC; Cancer Survivor 
Markey Cancer Center Patient 
Advisory Group 
George Harrison Cancer survivors and patients 
UK Central Appalachian Inter-
Professional Educational 
Collaborative (CAIPEC) 
Hann Solo, Primary 
Investigator 
Implementation of an opioid 
prevention program in the clinic 
UK Helping to End Addiction 
Long-term (HEAL) Initiative  
Leia Skywalker, Director Implementation of an interventional 
opioid research program in the 
community 
Voices of Hope  Paul McCartney, Co-founder Community-based opioid treatment 
referral agency; Recovering opioid 
addict 
Bluegrass Care Navigators Obi Wan Kenobi, Registered 
Nurse, 
External consultant for palliative 
care 
Cardinal Hill Rehabilitation 
Center,  
Ringo Starr, Director of 
Therapy Operations 
External consultant for long-term 
rehabilitation 
Kentucky Cabinet for Health 
and Family Services 
Fred Rogers, Social Worker Social Work 
Human Development Institute, 
Health and Wellness Initiative  
Bob Ross, Program Director Disabled population 
Lexington Fire & Emergency 
Services 
Jason Momoa,  
Fire Marshal 
First Responders for Ambulatory 
Services 
Table 10. Community Advisory Group  
Entity Personnel Area of Representation 
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APPENDICES 
Appendix A. DSM-IV-TR Diagnostic Categories for Substance Abuse and Substance Dependence 
Type Definition 
Nonmedical use Use of prescription drugs that were not prescribed by a medical professional (i.e., 
obtained illicitly) or use for the experience or feeling a drug causes. 
Misuse Incorrect use of a medication by patients, including: use a drug for a purpose other 
than that for which it was prescribed; take too little or too much of a drug; take it too 
often; or take it for too long (misuse does not apply to off-label prescribing) 
Abuse A maladaptive pattern of substance use, leading to clinically significant impairment 
or distress as manifested by one or more behaviorally based criteria. 
Physiological 
dependence 
Increasing tolerance for a drug, withdrawal signs and symptoms when a drug is 
discontinued, or the continued use of a substance to avoid withdrawal. 
Psychological 
dependence: 
A set of psychological symptoms that demonstrate overall loss of control or 
obsessive-compulsive drug-seeking and continued use of a substance in spite of 
clearly adverse consequences. Symptoms may include specific physiological signs 
of dependence such as increasing tolerance or withdrawal signs and symptoms when 
the drug is discontinued. 
Pseudoaddiction Drug-seeking and other behavior that is consistent with addiction but actually results 
from inadequate pain relief. Once the pain is adequately treated, the person no 
longer abuses the medication 
Appendix B. DSM-V Diagnostic Criteria for Substance Use Disorder 
1. The substance is often taken in larger amounts or over a longer period than was intended. 
 
2. There is a persistent desire or unsuccessful effort to cut down or control use of the   
     substance. 
3. A great deal of time is spent in activities necessary to obtain the substance, use the  
    substance, or recover from its effects. 
4. Craving, or a strong desire or urge to use the substance, occurs. 
5. Recurrent use of the substance results in a failure to fulfill major role obligations at work,  
    school, or home. 
6. Use of the substance continues despite having persistent or recurrent social or      
    interpersonal problems caused or exacerbated by the effects of its use. 
7. Important social, occupational, or recreational activities are given up or reduced because  
     of use of the substance. 
8. Use of the substance is recurrent in situations in which it is physically hazardous. 
9. Use of the substance is continued despite knowledge of having a persistent or recurrent  
    physical or psychological problem that is likely to have been caused or exacerbated by  
    the substance. 
10. Tolerance, as defined by either of the following: 
       a. A need for markedly increased amounts of the substance to achieve intoxication or  
            desired effect.  
       b. A markedly diminished effect with continued use of the same amount of the                 
           substance. 
11. Withdrawal, as manifested by either of the following:   
      a. The characteristic withdrawal syndrome for that substance (as specified in the DSM-5  
          for each substance). 
      b. The use of a substance (or a closely related substance) to relieve or avoid withdrawal    
          symptoms. 
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The Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-
IV-TR), provides diagnostic categories for substance abuse and substance dependence.56 There 
are six definitions to consider, the program approach in this grant intends to screen for all 
possible scenarios listed in Appendix A. The DSM-V replaced the separate categories of 
substance abuse and substance dependence with a single category: substance use disorder 
(SUD).56  The symptoms associated with an SUD fall into four major groupings: impaired 
control, social impairment, risky use, and includes the pharmacological criteria of tolerance and 
withdrawal. Depending on the substance, there are 10 or 11 criteria that can cause clinically 
significant impairment or distress, and must occur within a 12-month period.  There are three sub 
classifications—mild, moderate, and severe – which are determined by the number of present 
diagnostic criteria.57  Those who have two or three criteria are considered to have a “mild” 
disorder, four or five is considered "moderate," and six or more symptoms, "severe." The 
diagnostic criteria can be found in Appendix B.  
  Note that the terms ‘Tolerance’ and ‘Withdrawal’ are not used as diagnostic criteria for 
persons taking opioids prescribed for clinical care.  Doctors expect that patients will experience 
some tolerance when placed on an opioid medication and may need an increased dosage, 
especially during active cancer treatment. They also expect withdrawal effects when reducing a 
pain medication, and will effectively taper down the dosage to reduce unpleasant symptoms.  In 
these scenarios, the patient is not considered to have developed a substance use disorder unless at 
least three of the other criteria are present.56  
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Appendix C. Study Design, Eligibility, and Sample Size Calculation 
Study Design and Eligibility 
  This proposal will use a stepped-wedge study design, also known as a phased 
implementation, with each clinic serving as its own control.  Outcome metrics will be compared 
to baseline counts during the waiting period. This design is ideal from an ethical standpoint: this 
is a high-risk population and it is imperative that all eligible participants receive the intervention.     
  The inclusionary criteria are as broad as possible to replicate real-life scenarios.  Eligible 
participants will include adults aged 18 and older who score as Moderate or High risk on the 
SOAPP scale. All eligible participants will be in complete remission and transitioning to a 
survivorship phase, and all stages of cancer and treatment types will be included.  People with 
prior history of drug abuse and other pre-existing health conditions will also be included. If 
interested, the participant will be enrolled in the study screening procedures. Those with a score 
as moderate to high risk on the SOAPP opioid risk monitoring scale will be eligible to enroll in 
the study. Upon obtaining informed consent, the participant will receive the Screening, Brief 
Intervention, and Referral to Treatment intervention with motivational interviewing. Participants 
will then complete the COMM survey at the 3 month, 6 month, and 12 month follow-up 
appointments.  More information about timeline specifications can be found in the Performance 
Measures and Evaluation section. To measure whether the intervention is effective and not due 
to external factors, we will compare baseline counts for the outcome measures (number of 
referrals, etc.) versus post-implementation counts.  Specific details on the evaluation items we 
will measure can be found in the Outcome Evaluation section.  
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Sample Size Calculation 
 
According to the Markey Cancer Center 2017 Annual Report, there were a total of 619 
cases for breast (all sexes), prostate, and melanoma/skin cancers treated at MCC. These break 
out to 358 cases for breast, 153 cases for prostate, and 108 cases for melanoma/skin. 
Effect sizes were estimated based on the literature of SBIRT, with a Cohen’s d range 
from 0.17 to 1.35 within the interventional groups.58  Conventional medium effect size is 
accepted at 0.5, with a large effect size accepted at 0.8. Based on the clinic volume of 619 
patients treated last year for the specific disease sites, and the literature stating that 10% of 
cancer survivors were still being prescribed opioids 10 years past diagnosis, our initial 
assumption for the sample size would be around 100 people.  To determine the appropriate 
sample size, and since we knew how many patients have historically been treated at the clinic, 
we conducted a sample size for percent frequency in a population as a random sample.  With an 
effect size of 0.8, and anticipated percent frequency of OUD 10% in the population, we found 
that a sample size of 91 would be an acceptable target for recruitment. We expect to screen twice 
as many people as are eligible to participate, for a total of 300 people screened. 
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Appendix D. Screener and Opioid Assessment for Patients with Pain (SOAPP)® Version 1.0 - 
14Q 
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Appendix E. Current Opioid Misuse Measure (COMM) 
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Appendix F. Logic Model 
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Appendix G. Gantt Chart Year 1 Year 2 Year 3 
Activity Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 
Program Preparation, 
Training and Community 
Engagement 
Planning 
and 
Readiness 
Period                     
IRB Approval                         
Hire Key Staff                         
Order Supplies                         
Develop and test database 
and surveys                         
Educate and Train Key Staff 
and Clinic Providers                         
Community Advisory Group 
Formation and Meetings                         
Program Implementation                         
Failure Modes and Effects 
Analysis                         
Plan, Do, Study Act 
Worksheets                         
Implementation in Clinic 1 
(Q3, Month 7)                         
Implementation in Clinic 2 
(Q3, Month 9)                         
Implementation in Clinic 3 
(Q4, Month 11)                         
Data Collection in All 3 
Clinics - includes baseline 
measures                         
Evaluation and 
Maintenance                         
Key Informant Interviews                         
Process Evaluation                         
Fidelity Monitoring                         
Outcome Evaluation                         
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Appendix H. Plan, Do, Study, Act Cycle Worksheet 
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Appendix I. Organizational Chart 
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BUDGET JUSTIFICATION 
Primary Investigator: Hann Solo, DO, MHA, MPH; (10% / 5% / 5% FTE) Professor and Chief 
of Community Medicine, Director of the Kentucky Ambulatory Network (Practice Based 
Research Network). As the primary investigator of the CAIPEC grant funded by the Pfizer 
Consortium and a member of the Markey Cancer Center, Dr. Solo is well-suited to be the 
primary investigator of this grant.  His role will include forming the Community Advisory 
Group; oversee the Clinic Task Force and Practice Management Specialist; provide consultation 
to clinics and act as final authority on workflow changes; review high-level progress reports of 
the project to ensure milestones are being met in accordance with the funding sponsor’s 
guidelines; review potential participants’ screening files and approve enrollment; assist in hiring 
and termination of key staff; act as the emergency contact for Adverse Events and Serious 
Adverse Events; disseminate findings to CAG, Partners, and Stakeholders. 
Project Director: Jennifer M. Dolly Prothro, BA, MPH, CCRP;  (100% FTE) Mrs. Dolly 
Prothro has served the Markey Cancer Center in research administration for the last five years, 
prior to which she served as the Project Manager for three years on the clinical research project 
“Separate and combined effects of the gabapentin and THC in humans discriminating THC” 
[R01 DA025605] and a clinical trial to investigate the initial safety, tolerability and efficacy of 
the GABA reuptake inhibitor tiagabine to reduce cannabis use in daily cannabis users (R01 
DA036550; IND#101,109; clinicaltrials.gov ID NCT01511640. Her role will be to oversee all 
project staff other than the Clinic Task Force and Practice Management Specialist, monitor and 
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track progress, coordinate meetings, submit IRB documentation including protocol deviations 
and adverse events, and oversee dissemination of results.  
Clinic Providers (3) (5% FTE each)  
Clinic providers are expected to spend approximately 2 hours per week on the project. They will 
will be trained in motivational interviewing, opioid prescribing guidelines, appropriate pain 
management guidelines and therapies, and will be assessed per the Process Evaluation metrics. 
They will deliver the intervention to participants, provide referrals, and report interactions with 
each participant. 
Oncology Social Worker (60% / 70% / 80%FTE)  
Trains and assesses performance of providers and clinic champions in Motivational Interviewing. 
Assists in patient navigation. Mediator between providers, project staff, and participants. 
Behavioral Research Associates (2) (40% FTE each)  
Markey’s Behavioral and Community-Based Research Shared Resource Facility hosts a team of 
dedicated Behavioral Research Associates who are exceptionally well-trained in quantitative 
behavioral research.  Supports project implementation, screening, recruitment and tracking 
efforts, provides participant payments, review all data collection and ensure procedures have 
been followed according to Good Clinical Practice Guidelines, enter paper-based survey data, 
conduct minor data management as needed, create participant calendar schedules, etc. 
Biostatistician/Data Manager (5% FTE)  
Provides support for study design, study conduct, database building, and data management. 
Practice Management Specialist (5% FTE)  
Finds time savings in the clinic workflow to insert research protocol. 
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Clinic Task Force (2) (5% FTE each) 
 Maintains sustainability of protocol during project period, conducts Failure Modes and Effects 
Analysis. 
Consultant 
 $1,000 to consult on best-practices and issues as they arise in the project period.  
Equipment  
$5,000 to purchase two iPads for data collection, a camera to record motivational interviewing 
training sessions, and three laptops for participant screening, data entry, data management, 
participant recruitment, etc. 
Travel  
$3,000 in Year 1. $10,000 in Years 2 and 3. Provides travel funds for professional development 
opportunities for project staff.  
$6,000 for participant payments. Total of 1 screening appointment, and 3 
clinic visits at $5 each. Estimated 300 participants to be screened per year. 
Clinic Stipend 
$20,000 to pay the clinic as an incentive to allow the study protocol to be implemented in their 
clinic.  
Research Incentives 
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BUDGET 
 
